Last Updated: January 06, 2012.
Antivirals are cost-effective for injecting drug users where the chronic prevalence of hepatitis C virus infection is less than 60 percent, according to a study published in the January issue of Hepatology.
FRIDAY, Jan. 6 (HealthDay News) -- Antivirals are cost-effective for injecting drug users (IDUs) where the chronic prevalence of hepatitis C virus (HCV) infection is less than 60 percent, according to a study published in the January issue of Hepatology.
Natasha K. Martin, D.Phil., of the University of Bristol in the United Kingdom, and colleagues compared the cost-effectiveness of providing antiviral treatment for IDUs, ex or non-IDUs, or no treatment. They developed a model of HCV transmission and disease progression which incorporated assumptions including: a specified number of antiviral treatments to be given at the mild HCV stage over a period of 10 years, no retreatment for those who failed treatment, potential reinfection, and scenarios for baseline IDU HCV chronic prevalence of 20, 40, and 60 percent. Long-term costs and outcomes measured in quality adjusted life years (QALYs) were performed and the incremental cost-effectiveness ratio (ICER) was compared for no treatment, antiviral treatment for IDUs, and antiviral treatment for ex/non-IDUs.
The researchers found that, in the 20 and 40 percent baseline chronic prevalence settings, antiviral treatment for IDUs is the most cost-effective option compared with no treatment (ICER, £521 and £2,539 per QALY saved, respectively). Treatment of ex/non-IDUs dominated here. Treating ex/non-IDUs was slightly more likely to be cost-effective at a baseline chronic prevalence of 60 percent, and treating IDUs dominated due to high reinfection.
"Treating chronic HCV infection among injectors and ex- or noninjectors is cost-effective, but treating injectors may be more cost-effective when the chronic HCV prevalence among IDU is below 60 percent," the authors write.
Two of the study authors disclosed financial ties to the pharmaceutical industry.
Abstract
Full Text (subscription or payment may be required)
No comments:
Post a Comment